Project Grant R16AI203187
Award Date 9/2/26
Completion Date 8/31/30
Dollars Obligated $132K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Big Rapids, MI 49307, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $2.284 million on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on microbial interactions combating antibiotic-resistant bacteria (MI-CARB). The research employs a systems biology approach to understand pathogenesis of nosocomial infections caused by three pathogen groups: vancomycin-resistant enterococci (VRE),...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $234,000 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop sustainable production and derivatization of premarineosin A, a potent antimalarial compound. The project establishes premarineosin A as a next-generation antimalarial agent by developing metabolic engineering strategies to achieve sustainable production of the compound and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infection-induced cell cycle diversion and macrophage inflammatory biogenesis. The award funds investigation into how bacterial infection of macrophages, specifically by methicillin-resistant Staphylococcus aureus (MRSA), triggers structural and biochemical...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on April 1, 2026 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project examines the role of organelle membrane contact sites in macrophage antifungal immune responses, with particular focus on Candida albicans infection. Preliminary data indicate that the endoplasmic reticulum stress sensor IRE1A...
- The National Institute of Allergy and Infectious Diseases awarded $151,760 to the Regents of the University of Michigan on December 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support postdoctoral research characterizing riboswitches in methicillin-resistant Staphylococcus aureus as potential antibiotic targets. The fellowship provides advanced, multidisciplinary training in RNA biology, structural biochemistry, and single-molecule fluorescence...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $599,327 to Microbiotix, Inc. on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel benzyl-piperidine antifungal agents targeting intractable mucormycosis infections caused by drug-resistant Mucorales fungi. The project focuses on chemical optimization of a benzyl-piperidine series to improve drug-like properties and...
- The National Institute of Allergy and Infectious Diseases awarded Regents of the University of Michigan $411,078 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify novel antifungal compounds from symbiotic bacteria capable of combating drug-resistant Candida auris. The research exploits symbiotic bacteria—organisms that co-exist with and benefit their eukaryotic hosts—as a source of antifungal molecules with low mammalian toxicity. The...
- The National Institute of Allergy and Infectious Diseases awarded Oregon State University $495,688 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct mechanistic and structural studies of ureido bond formation in the biosynthesis of three families of bioactive bacterial natural products: anabaenopeptins, syringolins, and muramycins. The work dissects how bacteria assemble these ureido-containing molecules through non-ribosomal peptide...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases awarded The Medical College of Wisconsin, Inc. $649,014 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the conformation and functional dynamics of class B penicillin-binding proteins in enterococcal antimicrobial resistance. The project addresses the genetic and biochemical basis for cephalosporin resistance in antibiotic-resistant enterococci, which are major causes of...